Long-term urvivors of ovarian malignancies after cisplatin-base.docVIP

European Journal of Cancer European Journal of Cancer 40 (2004) 696-700 Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy: cardiovascular risk factors and signs of vascular damage F.Y.F.L. de Vosa, J. Nuvera, P.H.B. Willemsea, A.G.J. van der Zeeb, J. Messerschmidtc, J.G.M. Burgerhofd, E.G.E. de Vriesa, J.A. Gietemaa， ^Department of Medical Oncology, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands hDepartment of Gynaecological Oncology, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands Institute of Spectrochemistry and Applied Spectroscopy, Bunsen-Kirchhoff-Strasse 11, D-44139 Dortmund, Germany dDepartment of Epidemiology and Statistics, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands Received 25 November 2003; accepted 28 November 2003 Abstract Male germ cell tumour patients treated with cisplatin-based chemotherapy frequently develop cardiovascular risk factors and disease，but sparse information is available about long-term complications of this type of chemotherapy in women. We investigated the prevalence of cardiovascular risk factors and vascular damage in 21 women (median age 39 years; range 26-57 years) with an epithelial or germ cell tumour of the ovary cured by cisplatin-based chemotherapy after a median follow-up of 14 years (range 3-21 years). Hypercholesterolaemia was present in 62%，obesity in 24%，hypertension in 14%，insulin resistance in 14%，and microalbuminuria in 24% of patients. Microalbuminuria was more frequent in long-term cancer survivors than in a female background population with a similar age (23.8 versus 3.2%; P 0.05). A substantial portion of young female patients cured by cisplatin-based chemotherapy are likely to develop cardiovascular risk factors and signs of endothelial damage at an early stage. ? 2004 Elsevier Ltd. All rights reserved. Keywords: Germ cell tumour; Ovaries; cis-Platinum; Cardiovas